                         SEQUENCE LISTING

<110>  Shen, Haifa
 
<120>  ORALLY DELIVERED THERAPEUTICAL COMPOSITION AND USE THEREOF

<130>  C2002_01

<150>  US62896662
<151>  2019-09-06

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artificial sequence


<220>
<221>  Exendin-4 amino acid
<222>  (1)..(39)

<400>  1

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 
1               5                   10                  15      


Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Pro Ser 
        35                  


<210>  2
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artificial sequence


<220>
<221>  GLP-1 analogue amino acid
<222>  (1)..(31)
<223>  X or Xaa = Aib, alpha-aminoisobutyric acid, also known as 
       2-Aminoisobutyric acid.

<400>  2

His Xaa Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Arg Gly Arg Gly 
            20                  25                  30      


<210>  3
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Artifical mimic


<220>
<221>  microRNA-34a
<222>  (1)..(24)
<223>  microRNA-34a, Sense strand.

<400>  3
uggcaguguc uuagcugguu gutt                                              24


<210>  4
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Artificial mimic, antisense.


<220>
<221>  AntisensemicroRNA-34a
<222>  (1)..(24)
<223>  microRNA-34a antisense strand.

<400>  4
acaaccagcu aagacacugc catt                                              24


<210>  5
<211>  32
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  artificial peptide


<220>
<221>  Human brain natriuretic peptide
<222>  (1)..(32)
<223>  Human brain natriuretic peptide

<400>  5

Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp 
1               5                   10                  15      


Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His 
            20                  25                  30          


<210>  6
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  artificial peptide


<220>
<221>  Octreotide
<222>  (1)..(8)
<223>  Octreotide with D-Phe and D-Trp amino acid residues: D-Phe Cys 
       Phe D-Trp Lys Thr Cys Thr.

<400>  6

Phe Cys Phe Trp Lys Thr Cys Thr 
1               5               


<210>  7
<211>  24
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  artificial mimic


<220>
<221>  Let-7 mimic
<222>  (1)..(24)
<223>  Let-7 mimic.

<400>  7
cuguacagcc uccuagcuuu cctt                                              24


<210>  8
<211>  25
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Artificial mimic


<220>
<221>  miR-155 mimic
<222>  (1)..(25)
<223>  miR-155 mimic for to modulating immune responses.

<400>  8
uuaaugcuaa uugugauagg ggutt                                             25


<210>  9
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  human IRE1 siRNA


<220>
<221>  human IRE1 siRNA
<222>  (1)..(21)
<223>  human IRE1 siRNA sense strand for mmunomodulation and disease 
       treatment.

<220>
<221>  human IRE1 siRNA
<222>  (1)..(21)
<223>  human IRE1 siRNA sense strand for immunomodulation and disease 
       treatment.

<400>  9
gcacgugaau ugauagagat t                                                 21


<210>  10
<211>  28
<212>  PRT
<213>  Homo sapiens


<220>
<221>  human vasoactive intestinal polypeptide (VIP)
<222>  (1)..(28)
<223>  human vasoactive intestinal polypeptide (VIP)

<400>  10

His Ser Asp Ala Val Phe Thr Asp Asn Tyr Thr Arg Leu Arg Lys Gln 
1               5                   10                  15      


Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn 
            20                  25              


